Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Arvinas: Nothing Interesting In The Near Term
06:02pm, Monday, 12'th Jun 2023
Arvinas, Inc. has exciting science, but data has been a disappointment. There are no near-term major catalysts for Arvinas. Arvinas has a lot of cash, and is trading nearly at cash.
Arvinas to Participate in Upcoming Investor Conferences
07:00am, Monday, 05'th Jun 2023
NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
09:54am, Friday, 05'th May 2023
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss of $1.20 per share a year ago.
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
07:00am, Wednesday, 03'rd May 2023
NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou
Arvinas to Present at Stifel Targeted Oncology Day
04:00pm, Friday, 21'st Apr 2023
NEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?
04:36am, Friday, 14'th Apr 2023
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t
Arvinas to Participate in Upcoming Investor Conferences
04:00pm, Monday, 27'th Feb 2023
NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas to Participate in Upcoming Investor Conferences
04:30pm, Monday, 06'th Feb 2023
NEW HAVEN, Conn., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?
09:47am, Wednesday, 11'th Jan 2023
Arvinas, Inc. (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 04'th Jan 2023
NEW HAVEN, Conn., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas: Promising Science, Poor Data
04:12am, Monday, 05'th Dec 2022
ARVN has promising and novel science. This is the second time it produced underwhelming data.
Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates
09:48am, Tuesday, 08'th Nov 2022
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.53% and 31.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Arvinas, Inc. (ARVN): Can Its 12% Jump Turn into More Strength?
12:47pm, Thursday, 27'th Oct 2022
Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter
Arvinas to Present at Bank of America Securities Precision Oncology Conference
07:00am, Monday, 26'th Sep 2022
NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?
09:59am, Monday, 27'th Jun 2022
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t
